Interleukin-23 Inhibitors
Publisher
Galenos Yayinevi
Reference35 articles.
1. : Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics;Menter;J Am Acad Dermatol,2019
2. 2. Yeung J, Gooderham MJ, Grewal P, et al.: Management of Plaque psoriasis with biologic therapies in women of child-bearing potential consensus paper. J Cutan Med Surg 2020;24(Suppl1):3S-14.
3. Chiricozzi A, Antonioli L, Panduri S, Fornai M, Romanelli M, Blandizzi C: Risankizumab for the treatment of moderate to severe psoriasis;3;Expert Opin Biol Ther,2019
4. Amin M, Darji K, No DJ, Wu JJ: Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis;4;J Eur Acad Dermatol Venereol,2017
5. : Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial;Blauvelt;J Am Acad Dermatol,2017